Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDTX Cidara Therapeutics	$59.96 +6.8%	$34.15	$10.14 ▼ $61.26	$1.13B	1.14	212,594 shs	1.11 million shs
CRVS Corvus Pharmaceuticals	$4.26 +0.2%	$3.96	$2.10 ▼ $10.00	$289.72M	0.58	839,440 shs	441,874 shs
ELVN Enliven Therapeutics	$22.66 -2.9%	$20.02	$13.30 ▼ $30.03	$1.15B	0.83	306,262 shs	349,364 shs
GPCR Structure Therapeutics	$19.25 -1.4%	$21.73	$13.22 ▼ $45.37	$1.12B	-1.87	818,677 shs	1.64 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDTX Cidara Therapeutics	+7.44%	+10.36%	+154.07%	+188.84%	+331.59%
CRVS Corvus Pharmaceuticals	0.00%	0.00%	+7.87%	+31.17%	+95.85%
ELVN Enliven Therapeutics	+8.76%	+2.46%	+7.06%	+41.20%	-1.77%
GPCR Structure Therapeutics	-0.36%	+3.33%	-6.87%	-10.25%	-49.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDTX Cidara Therapeutics	3.6957 of 5 stars	2.6	2.0	4.6	4.0	1.7	0.0
CRVS Corvus Pharmaceuticals	2.8798 of 5 stars	3.5	1.0	0.0	3.3	3.3	0.6
ELVN Enliven Therapeutics	2.8657 of 5 stars	3.5	2.0	0.0	2.6	4.2	0.0
GPCR Structure Therapeutics	2.929 of 5 stars	3.5	3.0	0.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDTX Cidara Therapeutics	3.11	Buy	$57.29	-4.46% Downside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	252.11% Upside
ELVN Enliven Therapeutics	3.00	Buy	$41.20	81.82% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	295.67% Upside

Current Analyst Ratings Breakdown

Latest CRVS, ELVN, GPCR, and CDTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$69.00
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/30/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$59.00
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$35.00 ➝ $75.00
6/24/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$50.00 ➝ $68.00
6/23/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $53.00
6/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $54.00
6/23/2025	CDTX Cidara Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$45.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDTX Cidara Therapeutics	$1.27M	951.81	N/A	N/A	$14.92 per share	4.02
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.51 per share	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDTX Cidara Therapeutics	-$169.83M	-$29.47	N/A	N/A	N/A	N/A	-73.04%	-54.28%	8/12/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$0.98	N/A	N/A	N/A	N/A	-24.04%	-13.90%	8/5/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)

Latest CRVS, ELVN, GPCR, and CDTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ELVN Enliven Therapeutics	-$0.54	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDTX Cidara Therapeutics	N/A	3.87	3.87
CRVS Corvus Pharmaceuticals	N/A	4.90	4.90
ELVN Enliven Therapeutics	N/A	21.07	21.06
GPCR Structure Therapeutics	N/A	23.29	23.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDTX Cidara Therapeutics	35.82%
CRVS Corvus Pharmaceuticals	46.64%
ELVN Enliven Therapeutics	95.08%
GPCR Structure Therapeutics	91.78%

Insider Ownership

Company	Insider Ownership
CDTX Cidara Therapeutics	3.89%
CRVS Corvus Pharmaceuticals	28.50%
ELVN Enliven Therapeutics	25.90%
GPCR Structure Therapeutics	9.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDTX Cidara Therapeutics	90	20.16 million	19.38 million	No Data
CRVS Corvus Pharmaceuticals	30	68.17 million	48.74 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable

CRVS, ELVN, GPCR, and CDTX Headlines

Recent News About These Companies

Principal Financial Group Inc. Lowers Holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)

July 13, 2025 | marketbeat.com

Structure Therapeutics (NASDAQ:GPCR) Trading Down 7.3% - Here's Why

July 7, 2025 | marketbeat.com

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Rating of "Buy" from Brokerages

July 3, 2025 | marketbeat.com

Structure Therapeutics (NASDAQ:GPCR) Shares Down 4% - Here's Why

June 26, 2025 | marketbeat.com

Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT

June 24, 2025 | msn.com

Structure Therapeutics (NASDAQ:GPCR) Shares Up 4.7% - Time to Buy?

June 23, 2025 | marketbeat.com

Cantor Fitzgerald Reaffirms "Overweight" Rating for Structure Therapeutics (NASDAQ:GPCR)

June 23, 2025 | marketbeat.com

JMP Securities Reiterates "Market Outperform" Rating for Structure Therapeutics (NASDAQ:GPCR)

June 23, 2025 | marketbeat.com

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

June 20, 2025 | globenewswire.com

Structure Therapeutics: Why Aleniglipron's Path To Market Remains Treacherous

June 10, 2025 | seekingalpha.com

Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights

May 9, 2025 | finance.yahoo.com

Citigroup Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Buy Recommendation

May 3, 2025 | msn.com

Structure draws new Buy at Citi on oral obesity drug pipeline

May 2, 2025 | msn.com

Viking among notable gainers as Pfizer raises deal prospects

April 29, 2025 | msn.com

Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts?

April 26, 2025 | msn.com

H.C. Wainwright maintains buy on Structure Therapeutics shares

April 24, 2025 | uk.investing.com

Researchers crack the code of cell movement

April 24, 2025 | sciencedaily.comS

Eli Lilly jumps as results from weight-loss pill study rival competitor’s

April 17, 2025 | markets.businessinsider.com

Why did Lilly data for oral GLP-1 boost Structure and Metsera?

April 17, 2025 | seekingalpha.com

SA Asks: What's the best weight-loss drug stock right now?

April 17, 2025 | msn.com

Why Structure Therapeutics Inc.’s (GPCR) Stock Is Up 29.14%

April 17, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, ELVN, GPCR, and CDTX Company Descriptions

Cidara Therapeutics NASDAQ:CDTX

$59.96 +3.81 (+6.79%)

Closing price 04:00 PM Eastern

Extended Trading

$60.30 +0.34 (+0.57%)

As of 07:21 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Corvus Pharmaceuticals NASDAQ:CRVS

$4.26 +0.01 (+0.24%)

Closing price 04:00 PM Eastern

Extended Trading

$4.25 -0.01 (-0.33%)

As of 07:00 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Enliven Therapeutics NASDAQ:ELVN

$22.66 -0.68 (-2.91%)

Closing price 04:00 PM Eastern

Extended Trading

$22.68 +0.02 (+0.09%)

As of 04:20 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Structure Therapeutics NASDAQ:GPCR

$19.25 -0.28 (-1.43%)

Closing price 04:00 PM Eastern

Extended Trading

$19.21 -0.04 (-0.20%)

As of 06:52 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time